Sira 10

Drug Profile

Sira 10

Alternative Names: Sira-10

Latest Information Update: 14 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Siragen Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Psychiatric disorders

Highest Development Phases

  • Preclinical Alzheimer's disease; Psychiatric disorders

Most Recent Events

  • 08 Jul 2016 Sira 10 is available for licensing as of 08 Jul 2016.
  • 08 Jul 2016 Preclinical trials in Alzheimer's disease in USA (unspecified route)
  • 08 Jul 2016 Preclinical trials in Psychiatric disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top